BIO

Dr. Giorgio Gandaglia has been an Assistant Professor of Urology at Vita-Salute San Raffaele University in Milan since September 2020 and a Full Staff Urologist at San Raffaele Hospital since July 2017. He graduated with honors from Vita-Salute San Raffaele University in July 2011 and completed his Urology Residency there with honors in July 2017. Dr. Gandaglia enhanced his expertise through a 2013 Research Fellowship in Urologic Oncology at the University of Montreal Health Center, under Prof. Pierre I. Karakiewicz, and a 2015 fellowship at the OLV Robotic Surgery Institute in Belgium, under Prof. Alexandre Mottrie. Active in scientific societies, Dr. Gandaglia has been Chairman of the Prostate Cancer Group within the Young Academic Urologists (YAU) since November 2019. He was a member of the Scientific Committee of the Italian Society of Urology (SIU) from 2017 to 2021 and has been a Senior Associate Member of the EAU Prostate Cancer Guidelines Panel since November 2020. He also contributes to the EAU Robotic Urology Section (ERUS) and is a Board Member of the EAU Section of Uro-Oncology (ESOU) and ERUS. As a prolific researcher, Dr. Gandaglia has over 525 peer-reviewed publications and an H-Index of 58. He has been a Consulting Editor at European Urology since November 2020 and an Assistant Editor since January 2024. His accolades include the Reviewer of the Year award by European Urology (2015), the ESUI Vision Award (2019), the EAU Best Paper in Urological Literature Award (2019), the Matula Italian Award from SIU (2023), and the Crystal Matula Award from the EAU (2024) for the most promising scientific CV under 40.

LAB

Dr. Giorgio Gandaglia’s research spans several key areas in uro-oncology: health outcomes research, prostate cancer research, novel imaging modalities including PSMA PET, and artificial intelligence applications in urology. His work aims to advance the understanding and treatment of prostate cancer through innovative approaches and technologies, improving patient outcomes and contributing to the field.

Research activity

Dr. Gandaglia’s research is distinguished by his role as Principal Investigator in several innovative studies in the field of prostate cancer. He leads a trial on intraoperative PSMA PET (XEOS), investigating the use of this advanced imaging technique to enhance the detection and surgical management of prostate cancer. Additionally, he is the PI of a trial on artificial intelligence (QUANTIB prostate), which focuses on the application of AI to improve prostate cancer diagnosis and management using multiparametric MRI. A substantial portion of Dr. Gandaglia's research leverages the extensive URI database, which includes data on over 11,000 prostate cancer patients. The availability of detailed data on characteristics and outcomes of prostate cancer patients treated with radical prostatectomy allows for a wide array of studies aimed at improving clinical outcomes and advancing the understanding of prostate cancer epidemiology and treatment efficacy.

Dr. Gandaglia is actively involved as investigator in large international collaborative studies funded by IMI grants such as the PIONEER consortium, which utilizes big data to enhance prostate cancer research, and the OPTIMA project, aimed at optimizing personalized treatment for prostate cancer patients. Dr. Gandaglia's leadership in clinical trials and involvement in major research consortia highlight his pivotal role in advancing uro-oncological research on a global scale.

Click here to view our publications